The startup develops genetic cell modification technology to create engineered cell lines that produce therapeutic proteins and enhance immune cell therapies. By utilizing stem cell-derived tissues to express chimeric antigen receptors, the company enables targeted cancer treatment for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective cell therapies and biomanufacturing processes often requires complex and time-consuming genetic modification of cells. Traditional methods can be inefficient, lack precision, and involve costly viral vector production, hindering the rapid development and scalability of advanced therapies and biologics.
Solution
iO BiO Sciences offers GEMS™, a proprietary genetic cell modification technology that enables efficient, plug-and-play manufacturing of advanced therapy medicinal products and biomolecules. GEMS™ facilitates the development of off-the-shelf cell therapies in oncology using universal natural killer (NK) cells derived from a proprietary pluripotent stem cell line. The technology is also applicable to biomanufacturing, allowing for streamlined production of proteins or viral vectors in stable mammalian cell lines with a single variable: the gene of interest. GEMS™ reduces clone selection time and development costs by eliminating viral vector pools and enabling the repeated generation of the same clone.
Target Audience
The primary target audience includes biomanufacturing companies, developers of advanced therapy medicinal products, and researchers focused on cell therapy and oncology.
Features
- Genetic cell modification technology (GEMS™) for efficient gene editing
- Universal NK cell platform derived from a proprietary pluripotent stem cell
- Off-the-shelf CAR-NK cell therapies for oncology
- Streamlined biomanufacturing of proteins and viral vectors in mammalian cell lines
- Virus-free gene editing using electroporation
- Directed gene-editing for controlled integration
- Capability to generate millions of cell therapy doses from a single clone
- Allogeneic cell therapies facilitating an efficient off-the-shelf product model